Introduction. Despite continuous advances in assisted reproductive
technologies (ART), their outcomes are limited. Before introducing adjuvant
therapy to improve the in vitro fertilization (IVF) outcome, it is important
to identify appropriate groups of patients, and avoid equal approach for
everyone. Objective The objective of this paper was to review the available
literature on the most commonly used adjuvant therapy aiming to improve the
outcome of IVF. The guidelines of the European Society for Human
Reproduction and Embryology (ESHRE) and the American Society for
Reproductive Medicine (ASRM) were used, and the available literature was
analyzed by searching the Medline-PubMed and Cochrane databases using
appropriate keywords for each entity. Discussion. A review of the
literature found no consistent evidences for the standard use of metformin
in patients with polycystic ovarian syndrome (PCOSy), nor for use of
dehydroepiandrosterone (DHEA), testosterone (T) and growth hormone (GH) in
patients with premature ovarian failure or those with poor response to
stimulation. The standard usage of prednisone and aspirin in the general
population of patients in ART is also not recommended. Recently, the
significance of the oxidative stress has been emphasized, which is why the
use of antioxidants in the form of supplementation (Melatonin, vitamins C,
A, E, Coenzyme Q) might be important in improving reproductive outcomes.
Conclusion. The modern approach to the problem of infertility has become
strictly individual. The application of adjuvant therapy in order to improve
the outcome of ART procedures requires an analytical and critical approach
in each individual case.